geographic atrophy
Jump to navigation
Jump to search
Etiology
- macular degeneration
- advanced dry form of age-related macular degeneration
Epidemiology
- affects > 1 million people in the U.S. & 5 million people worldwide
Complications
- major cause of adult blindness
Management
- pegcetacoplan (Syfovre) injection administered every 25-60 days (FDA-approved)
- maximum benefit between 18-24 months after initiating treatment.
- avacincaptad pegol (Izeray)
- photovoltaic retina implant microarray (PRIMA) system
More general terms
References
- ↑ Marcus A FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. Medscape. February 17, 2023 https://www.medscape.com/viewarticle/988460
- ↑ 2.0 2.1 Holz FG, Le Mer Y, Muqit MMK et al Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. N Engl J Med 2026 Jan 15;394(3):232-242 PMID: https://pubmed.ncbi.nlm.nih.gov/41124203 PMCID: PMC7618305 Free PMC article. Clinical Trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2501396
Drew L People with blindness can read again after retinal implant. Nature News. 2025. Oct 20. https://www.nature.com/articles/d41586-025-03420-x